CLNN Clene Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CLNN

Price (delayed)

$0.4349

Market cap

$55.85M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.47

Enterprise value

$59.14M

Clene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new ...

Highlights
The revenue rose by 38% YoY but it fell by 9% QoQ
The gross profit has grown by 19% YoY but it has contracted by 15% from the previous quarter
The net income has shrunk by 65% YoY and by 23% QoQ
CLNN's quick ratio is down by 50% from the previous quarter and by 18% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://clene.com
Peers: OMER OMGA

Key stats

What are the main financial stats of CLNN
Market
Shares outstanding
128.43M
Market cap
$55.85M
Enterprise value
$59.14M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.17
Price to sales (P/S)
69.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
90.42
Earnings
Revenue
$654,000
EBIT
-$44.95M
EBITDA
-$42.81M
Free cash flow
-$30.5M
Per share
EPS
-$0.47
Free cash flow per share
-$0.29
Book value per share
$0.1
Revenue per share
$0.01
TBVPS
$0.5
Balance sheet
Total assets
$52.34M
Total liabilities
$38.95M
Debt
$32.16M
Equity
$13.39M
Working capital
$13.52M
Liquidity
Debt to equity
2.4
Current ratio
1.53
Quick ratio
1.39
Net debt/EBITDA
-0.08
Margins
EBITDA margin
-6,545.4%
Gross margin
81.5%
Net margin
-7,569.4%
Operating margin
-6,198.8%
Efficiency
Return on assets
-89.8%
Return on equity
-362%
Return on invested capital
-122.7%
Return on capital employed
-166.4%
Return on sales
-6,872.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CLNN stock price

How has the Clene stock price performed over time
Intraday
-1.16%
1 week
27.91%
1 month
6.86%
1 year
-53.29%
YTD
46.63%
QTD
2.23%

Financial performance

How have Clene's revenue and profit performed over time
Revenue
$654,000
Gross profit
$533,000
Operating income
-$40.54M
Net income
-$49.5M
Gross margin
81.5%
Net margin
-7,569.4%
The net income has shrunk by 65% YoY and by 23% QoQ
Clene's operating margin has increased by 39% YoY but it has decreased by 5% from the previous quarter
The revenue rose by 38% YoY but it fell by 9% QoQ
The company's net margin fell by 35% QoQ and by 20% YoY

Growth

What is Clene's growth rate over time

Valuation

What is Clene stock price valuation
P/E
N/A
P/B
4.17
P/S
69.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
90.42
CLNN's EPS is down by 2.2% since the previous quarter and by 2.2% year-on-year
The equity has contracted by 37% from the previous quarter
The stock's price to sales (P/S) is 92% less than its 5-year quarterly average of 826.9 and 28% less than its last 4 quarters average of 97.3
The revenue rose by 38% YoY but it fell by 9% QoQ

Efficiency

How efficient is Clene business performance
Clene's return on invested capital has shrunk by 142% YoY and by 36% QoQ
CLNN's return on sales is down by 37% since the previous quarter and by 22% year-on-year
The ROA has contracted by 34% YoY and by 18% from the previous quarter

Dividends

What is CLNN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLNN.

Financial health

How did Clene financials performed over time
The total assets is 34% greater than the total liabilities
The company's current ratio fell by 50% QoQ and by 27% YoY
CLNN's quick ratio is down by 50% from the previous quarter and by 18% YoY
The company's debt is 140% higher than its equity
Clene's debt to equity has shrunk by 76% YoY but it has surged by 61% QoQ
The equity has contracted by 37% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.